Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-043279
Filing Date
2025-05-14
Accepted
2025-05-14 16:02:15
Documents
78
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0239898-10q_oruka.htm   iXBRL 10-Q 1118051
2 PARUKA WARRANT, DATED DECEMBER 31, 2024 ea023989801ex4-5_oruka.htm EX-4.5 67901
3 CERTIFICATION ea023989801ex31-1_oruka.htm EX-31.1 12911
4 CERTIFICATION ea023989801ex31-2_oruka.htm EX-31.2 12606
5 CERTIFICATION ea023989801ex32-1_oruka.htm EX-32.1 7940
  Complete submission text file 0001213900-25-043279.txt   6813369

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE orka-20250331.xsd EX-101.SCH 66960
7 XBRL CALCULATION FILE orka-20250331_cal.xml EX-101.CAL 31574
8 XBRL DEFINITION FILE orka-20250331_def.xml EX-101.DEF 323411
9 XBRL LABEL FILE orka-20250331_lab.xml EX-101.LAB 545161
10 XBRL PRESENTATION FILE orka-20250331_pre.xml EX-101.PRE 342839
81 EXTRACTED XBRL INSTANCE DOCUMENT ea0239898-10q_oruka_htm.xml XML 843390
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 25945159
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)